
Adial Pharmaceuticals Receives Favorable Feedback from FDA Meeting on Proposed In-Vitro Bridging Strategy for AD04
FDA Feedback Affirms Adial’s In Vitro Bridging Strategy: A Game Changer for 505(b)(2) Registration In a recent development, the Food and Drug Administration (FDA) has confirmed Adial’s proposed in vitro bridging strategy to transition from the Phase 3 formulation to the proposed formulation for its 505(b)(2) regulatory registration. This announcement signifies a significant leap forward…